Sanofi US News

- Sanofi teams up with television personality Adam Savage and allergist Dr. Neeta Ogden to help dispel common allergy misconceptions with facts

* Precision medicine approach will focus efforts on high-risk patients, such as those who have had heart attacks or unstable angina and cannot reduce their LDL-C below 100 mg/dL despite maximally-tolerated statins

* ODYSSEY OUTCOMES trial met its primary endpoint, demonstrating that high-risk patients who added Praluent® (alirocumab) Injection to maximally-tolerated statins experienced significantly fewer major adverse cardiovascular events compared to those on maximally-tolerated statins alone

Companies also announce submission of dupilumab supplemental BLA for uncontrolled, persistent asthma

First study with a biologic to show benefit in severe steroid-dependent asthma population that enrolled patients regardless of blood eosinophil levels or any other Type 2 biomarkers at baseline

- Late-breaking oral abstract presented at the World Congress of Gastroenterology -

- Praluent continues to be available to patients in the U.S. -